BioSig Technologies began a deal to acquire the assets of Neuro-Kinesis Corporation (NKC), a privately-held, Los Angeles-based company developing smart electrophysiology (EP) tools.

NKC’s patented, catheter-based diagnostic system aims to address the limitations of EP mapping. The components of this system include the Huygens catheter and Proteus robotic arm.

The Huygens catheter has micro-electronics embedded in the tip to enable signal amplification and allow digital processing to take place at the point of signal capture. The signals are then digitized for transmission to the mapping station, eliminating corruption of the signal.

The catheter features a series of half-round electrodes so discrete measurements can be taken and analyzed from each electrode. It can also measure the tissue’s impedance in order to create a substrate conductivity map.

The Proteus robotic arm delivers computer-assisted robotic guidance for EP catheters to improve anatomical target acquisition during mapping. Its articulated limbs have 360-degree in any axis of direction and has ±0.1 mm to ±0.15 mm of precision control of the catheter.

Its Gripper, although designed for the Huygens catheter, can be used with any commercially available EP catheter that has a steering wheel design.

NKC also plans to focus on develop automated EP mapping systems that utilize artificial intelligence (AI)-based applications to respond to data received from the Huygens catheter and Ensite-X mapping station in real-time.

“The company’s management team and board of directors are strategically aligned to continue to execute attainable goals for 2024,” said BioSig CEO Anthony Amato. “We feel we have the ability to leverage our improving balance sheet, along with our expertise, to expand our product portfolio beyond PURE EP. With this in mind, we will continue to evaluate opportunities with a focus on new and exciting innovative technological platforms. I want to thank the NKC team for recognizing our complimentary core technologies and providing the initial due diligence. I look forward to the progression of this process.”

“I’m very excited about the potential collaboration with BioSig,” added NKC CEO Josh Shachar. “Joining forces will enable us to accelerate the market entry of our breakthrough technology for the diagnostic and therapeutic treatment of complex cardiac arrhythmias. For the last couple of decades, EP physicians have relied on an equal amount of historical results: the bioelectric voltage realms they can measure, and intuitive instincts they have learned to guide their healing art. The Huygens Catheter should allow them to finally be able to visualize the low-voltage landscape of the heart, where many believe the important information related to complex arrythmias lie.”